- Home
- SAVA vs CHEB Comparison
SAVA vs CHEB Comparison
Compare SAVA & CHEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- CHEB
- Stock Information
- Founded
- SAVA 1998
- CHEB 2024
- Country
- SAVA United States
- CHEB Singapore
- Employees
- SAVA N/A
- CHEB N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- CHEB
- Sector
- SAVA Health Care
- CHEB
- Exchange
- SAVA Nasdaq
- CHEB NYSE
- Market Cap
- SAVA 135.9M
- CHEB 119.4M
- IPO Year
- SAVA N/A
- CHEB 2024
- Fundamental
- Price
- SAVA $2.75
- CHEB $10.12
- Analyst Decision
- SAVA Buy
- CHEB
- Analyst Count
- SAVA 3
- CHEB 0
- Target Price
- SAVA $111.50
- CHEB N/A
- AVG Volume (30 Days)
- SAVA 3.4M
- CHEB 28.3K
- Earning Date
- SAVA 02-26-2025
- CHEB 01-01-0001
- Dividend Yield
- SAVA N/A
- CHEB N/A
- EPS Growth
- SAVA N/A
- CHEB N/A
- EPS
- SAVA N/A
- CHEB N/A
- Revenue
- SAVA N/A
- CHEB N/A
- Revenue This Year
- SAVA N/A
- CHEB N/A
- Revenue Next Year
- SAVA N/A
- CHEB N/A
- P/E Ratio
- SAVA N/A
- CHEB N/A
- Revenue Growth
- SAVA N/A
- CHEB N/A
- 52 Week Low
- SAVA $2.23
- CHEB $9.96
- 52 Week High
- SAVA $42.20
- CHEB $26.25
- Technical
- Relative Strength Index (RSI)
- SAVA 30.54
- CHEB N/A
- Support Level
- SAVA $2.65
- CHEB N/A
- Resistance Level
- SAVA $2.83
- CHEB N/A
- Average True Range (ATR)
- SAVA 0.24
- CHEB 0.00
- MACD
- SAVA 0.59
- CHEB 0.00
- Stochastic Oscillator
- SAVA 52.75
- CHEB 0.00
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.
About CHEB CHENGHE ACQUISITION II CO
Chenghe Acquisition II Co is a blank check company.